Research output per year
Research output per year
Personal profile
Research interests
I am interested in the development of new agents and treatment approaches for patients with myelodysplastic syndromes and acute myeloid leukemia. In conjunction with Drs. John DiPersio and Michael Rettig, we are currently conducting a Phase I/II Study of AMD3100 (plerixafor) in combination with mitoxantrone, etoposide and cytarabine for relapsed or refractory AML. AMD3100 is a CXCR4 antagonist currently under clinical development as a stem cell mobilizing agent for use in hematopoietic transplantation. Preclinical evidence suggests that AMD3100 can disrupt the interaction of leukemic blasts with the bone marrow microenvironment sensitizing these cells to genotoxic stresses such as chemotherapy. This trial is designed as a proof of concept study to determine if AMD3100 "priming" can improve response rates in AML.
Clinical interests
Bone marrow transplant, oncology, cancer, lymphoma, leukemia, aplastic anemia
Fingerprint
Dive into the research topics where Geoffrey Uy is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Acute Myeloid Leukemia, Version 3.2023
Pollyea, D. A., Altman, J. K., Assi, R., Bixby, D., Fathi, A. T., Foran, J. M., Gojo, I., Hall, A. C., Jonas, B. A., Kishtagari, A., Lancet, J., Maness, L., Mangan, J., Mannis, G., Marcucci, G., Mims, A., Moriarty, K., Ali, M. M., Neff, J., Nejati, R., & 17 others, May 2023, In: JNCCN Journal of the National Comprehensive Cancer Network. 21, 5, p. 503-513 11 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612
Assouline, S., Michaelis, L. C., Othus, M., Hay, A. E., Walter, R. B., Jacoby, M. A., Schroeder, M. A., Uy, G. L., Law, L. Y., Cheema, F., Sweet, K. L., Asch, A. S., Liu, J., Moseley, A. B., Maher, T., Kingsbury, L. L., Fang, M., Radich, J., Little, R. F. & Erba, H. P., 2023, In: Leukemia and Lymphoma. 64, 2, p. 473-477 5 p.Research output: Contribution to journal › Letter › peer-review
-
Clonal hematopoiesis in survivors of childhood cancer
Friedman, D. N., Chan, I. C. C., Moskowitz, C. S., Li, S., Turner, K., Liu, J., Bouvier, N., Walsh, M. F., Spitzer, B., Kung, A. L., Berger, M., Cooper, M., Pusic, I., Uy, G., Link, D., Druley, T. E., Diaz, L. A., Levine, R. L., Shukla, N. & Bolton, K. L., Aug 8 2023, In: Blood Advances. 7, 15, p. 4102-4106 5 p.Research output: Contribution to journal › Letter › peer-review
Open Access -
Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma
Barnell, E. K., Skidmore, Z. L., Newcomer, K. F., Chavez, M., Campbell, K. M., Cotto, K. C., Spies, N. C., Ruzinova, M. B., Wang, T., Abro, B., Kreisel, F., Parikh, B. A., Duncavage, E. J., Frater, J. L., Lee, Y. S., Hassan, A., King, J. A., Kohnen, D. R., Fiala, M. A., Welch, J., & 6 others, Jan 24 2023, In: Blood Advances. 7, 2, p. 236-245 10 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study
Bhatnagar, B., Kohlschmidt, J., Orwick, S. J., Buelow, D. R., Fobare, S., Oakes, C. C., Kolitz, J. E., Uy, G., Stock, W., Powell, B. L., Nicolet, D., Hertlein, E. K., Mrózek, K., Blachly, J. S., Eisfeld, A. K., Baker, S. D. & Byrd, J. C., Aug 16 2023, In: Blood Advances. 7, 16, p. 4671-4675 5 p.Research output: Contribution to journal › Letter › peer-review
Open Access1 Scopus citations